US Biopharmaceutical Company Liminatus Pharma Plans to Raise $500 Million to Invest in BNB
BlockBeats News, July 28th, According to a report by businessinsider, Clinical-stage biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ: LIMN) today announced plans to strategically expand into the cryptocurrency and blockchain space.
The company plans to establish a subsidiary named "American BNB Strategy" to lead its digital asset investment and management plan. Through this platform, Liminatus plans to gradually raise and deploy up to $500 million in funds, with the goal of strategically long-term investing in BNB.
Liminatus emphasized that while the company remains fully committed to its core business - advancing cancer treatments and pancreatic cancer diagnostic technologies, expanding into the digital asset space is seen as a necessary step to support long-term growth and enhance shareholder value.
Liminatus is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer patients. The company is advancing a series of novel therapies targeting cancer antigens and tumor-specific immune responses.
También te puede gustar
Ganadores
Últimas noticias cripto
Trump dice que el presidente de la Fed debería recortar las tasas de interés y reitera críticas a Powell
En las últimas 24 horas, toda la red liquidó $376 millones, con la mayoría proveniente de la posición corta más grande
La probabilidad de un recorte de la tasa de interés de 25 puntos básicos por parte de la Reserva Federal en diciembre se encuentra actualmente en 87.2%.
Trump: Anunciará nuevo presidente de la Fed a principios del próximo año
El sitio web de Coinbase International lanzará el comercio perpetuo de contratos de DASH
Atención al cliente:@weikecs
Cooperación comercial:@weikecs
Trading cuantitativo y MM:[email protected]
Servicios VIP:[email protected]